Tenaya Therapeutics (TNYA) said Tuesday that preliminary data from the first cohort of three patients in a phase 1b/2 trial showed that its TN-201 gene therapy was well tolerated, with no cardiac toxicities or severe adverse effects.
TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy, a condition caused by insufficient levels of myosin-binding protein C, the company said.
Tenaya said the initial results demonstrated "readily detectable vector DNA in the heart, evidence of transgene RNA expression, and increasing TN-201 mRNA and MyBP-C protein levels over time."
Tenaya Therapeutics shares were down 12% in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。